StockVS

DSS, Inc. (DSS) Stock Analysis

Consumer Cyclical

DSS, Inc.

$0.53

+$0.02 (+4.16%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

DSS, Inc. operates as a diversified entity within the United States, managing operations across product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing businesses. Specifically, the company manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions, highlighting a diverse operational footprint that spans both physical manufacturing and financial services sectors. The firm is classified within the Consumer Cyclical sector and the Packaging & Containers industry, positioning it as a business whose performance is theoretically tied to consumer spending patterns and industrial demand for packaging materials. Despite this broad scope, the company maintains a relatively small scale with a market capitalization of $9.64M and employs approximately 100 people. The annual revenue generated is $22.05M, which, when combined with the low market cap, indicates that the company operates as a micro-cap entity with limited market presence relative to larger peers in the packaging industry.

Financial Health

The company reports a Trailing Twelve Months (TTM) revenue of $22.05M, yet simultaneously records a net income loss of $42,046,000 and an EBITDA of $-38,784,000. The significant gap between the positive revenue figure and the substantial negative net income reveals a highly distressed cost structure where operating expenses and other liabilities far exceed the gross revenue generated by the business. While the income statement shows deep losses, the balance sheet indicates a surprising degree of cash generation, with Free Cash Flow reported at $26.89M, suggesting the company retains significant cash from operations despite accounting losses. This positive cash flow provides a degree of financial flexibility that contrasts sharply with the reported earnings, potentially allowing the firm to cover debt obligations or fund operations without immediate external financing. The company holds $8.68M in cash assets against $56.68M in total debt, resulting in a debt-to-equity ratio of 217.10, which indicates a highly leveraged balance sheet rather than a conservative one. Liquidity is constrained by a current ratio of 0.32, indicating that the company possesses only 32 cents of current assets for every dollar of current liabilities, signaling potential short-term liquidity challenges. Furthermore, the Return on Equity stands at -100.3% and the Return on Assets is -22.1%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the company.

Valuation Assessment

The valuation metrics for DSS, Inc. present a complex picture, with a P/E Ratio (TTM) listed as N/A due to negative earnings and a Forward P/E of -1.21. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in a continued expectation of negative earnings in the near future. The Price to Book ratio is 0.62, which indicates that the stock is trading at a discount to its book value, suggesting the market values the company's assets at less than their recorded accounting value. Alternative valuation metrics show a Price to Sales ratio of 0.44 and an EV/EBITDA of -1.77, figures that suggest the market is not applying a traditional growth premium but rather a deep discount based on the company's negative earnings power and high debt load. Regarding price momentum, the stock has traded between a 52-Week High of $1.90 and a 52-Week Low of $0.72, and the current price sits within this range, reflecting the volatility inherent in small-cap biotechnology and packaging firms. The stock exhibits a Beta of 1.29, meaning its price volatility is approximately 29% higher than the broader market, indicating that the stock is significantly more sensitive to market fluctuations than large-cap index constituents.

Growth & Income

DSS, Inc. demonstrates a Revenue Growth (YoY) of 14.2%, while the Earnings Growth (YoY) is N/A due to the company's negative net income position. The divergence between positive revenue growth and the absence of earnings growth implies that the company is expanding its top line but is currently unable to translate that expansion into profitability. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that the firm does not distribute cash to shareholders and instead reinvests any available cash flow into its operations or debt reduction. The overall growth and income profile is characterized by revenue expansion paired with significant operational losses and no income distribution, creating a high-risk environment where future profitability is the primary catalyst for any potential change in valuation.

Peer Comparison

DSS, Inc. (DSS) operates in the Packaging & Containers industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
DSS, Inc. DSS $5.28M N/A
Smurfit Westrock Plc SW $20.56B 54.4
Packaging Corporation of America PKG $19.24B 26.2
Amcor plc AMCR $18.01B 31.2

The Packaging & Containers industry average P/E ratio is 23.9x. DSS, Inc. trades at a P/E of N/A.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About DSS, Inc.

DSS, Inc. operates in the product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing businesses in the United States. The company manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. It invests in or acquires companies in the biohealth and biomedical fields, including businesses that focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases; and develops open-air defense initiatives for air-borne infectious diseases comprising tuberculosis and influenza. In addition, the company focuses on acquiring equity positions in undervalued commercial banks, bank holding companies, and nonbanking licensed financial companies; and companies engages in nonbanking activities related to banking, such as loan syndication, mortgage banking, trust and escrow, banking technology, loan servicing, equipment leasing, problem asset management, special purpose acquisition company consulting, and advisory capital raising services. Further, the company provides securities and investment management services; and operates a real estate investment trust for acquiring hospitals and other acute or post-acute care centers. Additionally, it develops and acquires assets and investments in the securities trading and funds management arena, as well as lists and operates as a digital asset on secondary market. The company was formerly known as Document Security Systems, Inc. and changed its name to DSS, Inc. in September 2021. DSS, Inc. was incorporated in 1984 and is headquartered in West Henrietta, New York.

Visit website →

Key Statistics

Market Cap
$5.28M
P/E Ratio
N/A
52-Week High
$1.90
52-Week Low
$0.49
Avg Volume
64.41K
Beta
1.00

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
AMEX
Country
United States
Employees
102